Clinical trials
Active, not recruiting Lymphoma, B-Cell, Marginal Zone trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
37 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 37 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| City of Hope Medical Center | 5 |
| Memorial Sloan Kettering Cancer Center | 3 |
| AbbVie | 2 |
| Barbara Ann Karmanos Cancer Institute | 2 |
| National Cancer Institute (NCI) | 2 |
| Sana Biotechnology | 2 |
| Acerta Pharma BV | 1 |
| Adicet Therapeutics | 1 |
| ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 1 |
| BeOne Medicines | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, B-Cell, Marginal Zone | 37 |
| Lymphoma, Follicular | 26 |
| Lymphoma, Mantle-Cell | 22 |
| Lymphoma, Large B-Cell, Diffuse | 20 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 15 |
| Lymphoma, Non-Hodgkin | 14 |
| Waldenstrom Macroglobulinemia | 12 |
| Lymphoma, B-Cell | 10 |
| Burkitt Lymphoma | 7 |
| Recurrence | 5 |
Trials
Showing 1 to 25 of 37. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.